Reasons for Discontinuation of First Highly Active Antiretroviral Therapy in a Cohort of Proteinase Inhibitor–Naive HIV-Infected Patients
- 1 February 2001
- journal article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 26 (2) , 191-193
- https://doi.org/10.1097/00126334-200102010-00016
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patientsAIDS, 2000
- Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in AdultsNew England Journal of Medicine, 1999
- Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort studyThe Lancet, 1999
- Analysis of the Discontinuation of Protease Inhibitor Therapy in Routine Clinical PracticeScandinavian Journal of Infectious Diseases, 1999
- Changing patterns of mortality across Europe in patients infected with HIV-1The Lancet, 1998
- Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitorAIDS, 1998
- Predictors of long-term response to protease inhibitor therapy in a cohort of HIV-infected patientsAIDS, 1998
- Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral TherapyNew England Journal of Medicine, 1997